BIO Targets 340B Hospital Acquisitions Of Oncology Practices In Study
This article was originally published in The Pink Sheet Daily
In an effort to support its claim that the 340B drug discount program is being used by hospitals to generate profits, the Biotechnology Industry Organization released a study finding use of 340B drugs at physician-based oncology practices grew significantly after they were acquired by hospitals.
You may also be interested in...
Differences in covered costs were greatest for Avastin, Lemtrada, Perjeta and Rituxan, among 10 commonly prescribed drugs studied, IMS found. Patient cost sharing was an average $134 higher per dose in hospitals.
A group supported by drug manufacturers and pharmacy benefit managers – the Alliance for Integrity and Reform of 340B – is pushing Congress to alter how hospitals qualify for discounted drugs under the 340B program.
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.